TY - JOUR
T1 - Safety overview of new disease-modifying antirheumatic drugs
AU - Cush, John J.
PY - 2004/5
Y1 - 2004/5
N2 - The use of novel DMARDs (leflunomide, anakinra, TNF inhibitors) has produced newfound levels of patient satisfaction. The toxicities detailed herein are often mild to moderate, often resolve or are well tolerated, and seldom warrant discontinuation of the drug. Serious and potentially life-threatening adverse events are rare, even in the postmarketing era. Clinicians should be mindful of these rare adverse events (eg, tuberculosis or lymphoma) and should counsel patients appropriately based on their concerns and quality of life. Because many of these serious toxicities occur at rates of 1 or fewer cases per 1000 patient years of use, it appears that proper patient selection and prevention measures are needed to further limit this risk.
AB - The use of novel DMARDs (leflunomide, anakinra, TNF inhibitors) has produced newfound levels of patient satisfaction. The toxicities detailed herein are often mild to moderate, often resolve or are well tolerated, and seldom warrant discontinuation of the drug. Serious and potentially life-threatening adverse events are rare, even in the postmarketing era. Clinicians should be mindful of these rare adverse events (eg, tuberculosis or lymphoma) and should counsel patients appropriately based on their concerns and quality of life. Because many of these serious toxicities occur at rates of 1 or fewer cases per 1000 patient years of use, it appears that proper patient selection and prevention measures are needed to further limit this risk.
UR - http://www.scopus.com/inward/record.url?scp=2542485453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2542485453&partnerID=8YFLogxK
U2 - 10.1016/j.rdc.2004.02.003
DO - 10.1016/j.rdc.2004.02.003
M3 - Review article
C2 - 15172038
AN - SCOPUS:2542485453
SN - 0889-857X
VL - 30
SP - 237
EP - 255
JO - Rheumatic Disease Clinics of North America
JF - Rheumatic Disease Clinics of North America
IS - 2
ER -